60 results about "Phosphoprotein" patented technology

The invention belongs to the technical field of biology, and relates to a biomarker for early diagnosis of non-small cell lung cancer and application of the biomarker. The biomarker comprises a combination of secretory phosphoprotein 1, epithelial cell adhesion molecules and matrix metallopeptidase 14, and / or a combination of coding nucleic acid of the secretory phosphoprotein 1, coding nucleic acid of the epithelial cell adhesion molecules and coding nucleic acid of the matrix metallopeptidase 14. The coding nucleic acid comprises mRNA or cDNA. In a test set, a non-small cell lung cancer circulating tumor cell scoring diagnosis model constructed by taking the biomarker as the characteristic has the diagnosis accuracy of 87.5% and the sensitivity and specificity of 92.5% and 82.5% respectively. Compared with existing clinical tumor indexes, cancer can be found more early, and early screening of the non-small cell lung cancer is facilitated.

The invention discloses an egg source calcium absorption promoting polypeptide as well as a preparation method and application thereof, and belongs to the technical field of polypeptides. The egg source calcium absorption promoting polypeptide comprises phosvitin source polypeptide or shell membrane source polypeptide; the amino acid sequence of the phosvitin source polypeptide is LSKIWGR, and the amino acid sequence of the shell membrane source polypeptide is GPAGFPGAP. Two egg source polypeptides LSKIWGR and GPAGFPGAP are screened and identified for the first time, a physicochemical activity binding cell model is adopted for evaluating the calcium absorption promoting function of the polypeptides, and it is found that the two polypeptides not only can be efficiently bound with calcium ions, but also have certain capacity of improving the transcellular membrane transport activity of calcium elements, and can promote absorption of the calcium ions. The two egg source polypeptides provided by the invention have the potential of being developed and prepared into related products for supplementing calcium and / or promoting calcium absorption.

Provided herein is an antibody having specificity for nucleophosprotein 1 (NPM1), which is capable of binding to nucleophosprotein 1 located on the surface of a cell; and antibody-drug conjugates (ADCs) comprising such antibodies are provided. Also provided herein are methods of treating a cancer in which NPM1 is expressed on the surface of a cancer cell by administering to a subject an NPM1-binding antibody or antibody conjugate as described herein and a chemotherapeutic drug.

The present invention relates to improved complexes of amorphous calcium phosphate and / or calcium by amorphous fluoride phosphate stabilised phosphopeptides / phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental / medical applications (including anti-calculus, anti-erosion / corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion / corrosion and dental hypersensitivity are also provided.

The present invention relates to improved complexes of amorphous calcium phosphate and / or amorphous calcium fluoride phosphate stabilised by phosphopeptides / phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental / medical applications (including anti-calculus, anti-erosion / corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion / corrosion and dental hypersensitivity are also provided.

The invention discloses a biomarker for detecting advanced non-small cell lung cancer and application of the biomarker. The biomarker comprises a combination of secretory phosphoprotein 1, epithelial cell adhesion molecules, keratin 19 and matrix metallopeptidase 14, and / or a combination of coding nucleic acid of the secretory phosphoprotein 1, coding nucleic acid of the epithelial cell adhesion molecules, coding nucleic acid of the keratin 19 and coding nucleic acid of the matrix metallopeptidase 14. The coding nucleic acid comprises mRNA or cDNA. The advanced non-small cell lung cancer accompanying diagnosis model constructed by using the biomarker is accurate and reliable, and can dynamically monitor the subsequent state of a patient and early warn the disease progress.

The application provides a kind of double ligand HOF functionalized magnetic nanomaterial and its preparation method and application, belongs to functionalized magnetic material preparation technical field.The method first synthesizes Fe3O4NPs, NH3·H2O is added to solution to be alkaline, then the temperature is heated to react, obtains Fe3O4NPs suspension liquid;Fe3O4NPs suspension liquid is added to oleic acid stirring, and the obtained Fe3O4@OA;Guanidine hydrochloride monomer is dissolved in solvent, then Fe3O4@OA is dispersed in stirring, and Fe3O4@GD is obtained;Finally, Fe3O4@GD is mixed with GD, boric acid, triethylamine and 1,2,4-trichlorobenzene containing solution stirring, and double ligand HOF functionalized magnetic nanomaterial is obtained.The functional material of the application can also effectively capture glycoprotein, and identify glycoprotein and phosphoprotein.

A method for detection or monitoring status of traumatic brain injury (TBI) and / or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP / FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP / FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

The invention provides an extraction method of egg phosvitin, the egg phosvitin is extracted by a magnetic separation technology by preparing a pH-sensitive composite magnetic nanogel, the pH-sensitive composite magnetic nanogel takes a magnetic porous gel as an inner core, after the surface of the magnetic porous gel is modified by polydopamine and athomin, the pH-sensitive composite magnetic nanogel is added into the magnetic porous gel, and the pH-sensitive composite magnetic nanogel is subjected to magnetic separation to obtain the egg phosvitin. And forming a sulfhydrylation shell layer, and connecting iron ions to the sulfhydrylation shell layer. According to the method, polydopamine combined on the surface of the magnetic porous gel can be rapidly combined with athomin with sulfydryl, and a sulfhydrylation shell layer is beneficial to combination of iron ions, so that egg phosvitin can be rapidly separated out under the action of an external magnetic field, finally, the external magnetic field is removed, and the egg phosvitin is placed in an alkaline environment; the egg phosvitin can be safely and efficiently separated out.

An antisense oligonucleotide (ASO) that is capable of binding to a target sequence in a mRNA of a secreted phosphoprotein 1 (SPP1) or osteopontin (OPN) gene, the mRNA having a start codon in an open reading frame encoding the SPP1 or OPN, and the target sequence including the start codon in the open reading frame of the mRNA. Binding of the ASO to the target sequence disrupts translation of the ORF encoding the SPP1 or OPN. Alternatively, an ASO wherein the ASO is capable of binding to a target sequence in a pre-mRNA of a SPP1 or OPN gene. Also double-stranded DNA or RNA molecules capable of binding to a target sequence in a mRNA or pre-mRNA of a SPP1 or OPN gene. Additionally, pharmaceutical compositions and methods of treatments using the ASOs or double-stranded DNA or RNA molecules.

The present invention provides a temperature-sensitive negative-strand RNA virus or virus vector and an RNA genome thereof. According to the invention, provided is a negative-strand RNA virus or virus vector having a negative-strand RNA genome wherein the phosphoprotein (P protein) on the RNA genome has an amino acid mutation(s) corresponding to a substitution(s) in an amino acid(s) of the P protein corresponding to one or more or all of D433, R434, and K437 and optionally further has an amino acid mutation corresponding to a further amino acid substitution in an amino acid of the P protein corresponding to L511.

Provided are oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLN RNA in a cell or animal, and in certain instances reducing the amount of phospholamban protein in a cell or animal. Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat cardiomyopathy, heart failure, or arrhythmia.

To provide a novel treatment method for treating organ fibrosis in a subject.SOLUTION: A method for treating organ fibrosis in a subject comprises administering to a subject a therapeutically effective amount of one or more antibodies or antigen binding fragments thereof that bind to and block soluble ephrin-B2 ectodomain.SELECTED DRAWING: None

The invention provides application of phosvitin and phosphopeptides thereof in preparation of in-vitro anticoagulant drugs, specifically, blood coagulation is caused by a series of enzymatic reactions, the chemical nature of the blood coagulation is that fibrinogen in a sol state is converted into fibrin in a gel state, and the main substance for catalyzing the reactions is thrombin. The phosvitin can inhibit the activity of thrombin in blood so as to prolong the blood coagulation time to achieve the anticoagulation effect. The application proves that phosvitin has the potential of being developed into an in-vitro anticoagulant.

This invention relates to the field of biomedical technology, specifically to a composite adsorption material for enriching phosphopeptides of egg yolk high-phosphoproteins and its preparation method. The material comprises, from the inside out: Zr 4+ and La 3+ A bimetallic-doped TiO2 matrix, an EDTA passivation layer, and an amino-functionalized layer were co-doped. The preparation process included: synthesizing the bimetallic-doped TiO2 matrix via a sol-gel method, passivating and coating it with EDTA solution after two-step calcination, and then grafting the amino layer using APTES / acetic acid catalysis. This material exhibits both high specific surface area and specific binding capacity, achieving an adsorption capacity of 67.5 mg / g. After 10 cycles, the capacity retention rate is >92.8%, enabling efficient enrichment of high-purity PPPs, making it suitable for the industrial production of functional foods and pharmaceuticals.

A method for detection or monitoring status of traumatic brain injury (TBI) and / or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP / FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP / FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

The present invention relates to improved complexes of amorphous calcium phosphate and / or amorphous calcium fluoride phosphate stabilised by phosphopeptides / phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental / medical applications (including anti-calculus, anti-erosion / corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion / corrosion and dental hypersensitivity are also provided.

The invention discloses a method for screening biomarkers for storing platelet quality in combination with multi-omics and machine learning and application of the method, and belongs to the technical field of biology. According to the method, platelet aggregation, activation and blood routine index detection data and proteome, phosphorylated proteome and metabolome data collected from single platelet samples are comprehensively analyzed, and a machine learning model for predicting the quality of stored platelets is developed; 15 biomarker groups capable of indicating the quality of the stored platelets are screened out, and comprise 12 phosphorylated proteins, 1 protein and 2 metabolites. The invention provides a new path and a new method for improving platelet storage conditions in a blood station, establishing a novel platelet quality detection means, developing products indicating the quality of stored platelets and improving the platelet utilization rate.

The present invention relates to a method for rescue of Vesicular Stomatitis Virus (VSV) from DNA in a HEK293 cell line or a HEK293 cell line adapted to suspension growth comprising (a) providing cells from a HEK293 cell line or a HEK293 cell line adapted to suspension growth in cell culture, (b) transfecting the cells with at least one plasmid, wherein the at least one plasmid comprises (i) an expression cassette comprising a VSV genomic cDNA; (ii) at least one expression cassette encoding VSV nucleoprotein (N) protein, VSV phosphoprotein (P) protein, and VSV large (L) protein; and (iii) an expression cassette encoding SV40 Large T antigen; (c) culturing the transfected cells; and (d) harvesting the cell culture supernatant comprising the rescued VSV. Also provided is the use of a HEK293 cell line or a HEK293 cell line adapted to suspension growth for rescue of Vesicular Stomatitis Virus (VSV) or the use of a plasmid encoding SV40 Large T antigen for rescue of Vesicular Stomatitis Virus (VSV) in a HEK293 cell line or a HEK293 cell line adapted to suspension growth HEK293-F cells by means of transient transfection.

Provided herein are methods of treating acute leukemia, e.g., acute myeloid leukemia (AML), in an individual, e.g., an individual having a mutation in the nucleophosmin 1 (NPM1) gene or a rearrangement in the lysine [K]-methyltransferase 2A (KMT2A) gene, the methods comprising administering the menin inhibitor diftomenib to the individual at a dose of 600 milligrams daily.

To reduce the amount or activity of PLN RNA in cells or animals, in certain cases, oligomeric compounds, methods, and pharmaceutical compositions are provided for reducing the amount of phospholamban protein in cells or animals. Such oligomeric compounds, methods, and pharmaceutical compositions are useful for treating cardiomyopathy, heart failure, or arrhythmias.

To provide a combination treatment, a composition and a kit comprising (a) a long-acting IL-15 receptor agonist and (b) one or more antibodies (mAb) targeting a tumor antigen, and related methods of preparation and use, e.g., in treatment of conditions responsive to therapy effective to provide sustained immune activation and anti-tumor activity.SOLUTION: In some embodiments, antibodies bind specifically to a tumor antigen selected from a phosphoprotein, a transmembrane protein, a glycoprotein, a glycolipid and a growth factor. In further embodiments of the methods, a subject has a solid cancer.SELECTED DRAWING: None

A method of treating a subject having an articular disorder by administration of a long-acting liposomal composition. A preferred liposomal composition includes a phosphatidylcholine as the sole active ingredient, wherein the phosphatidylcholine is selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, N-palmitoyl-D-erythro-sphingosylphosphorylcholine, and a combination thereof. A preferred administration is by a single intra-articular injection once or every 4 to 12 months to afford pain relief and / or reduction of irritation in the joint of the subject.

The present disclosure relates to virus-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial virus (RSV) infection. Specifically, the disclosure provides virus like-particles (VLPs) for use in inducing immunity to respiratory syncytial virus (RSV) infections or symptoms thereof, wherein the VLP comprising a respiratory RSV matrix protein (M) and an RSV M2-1 protein, a glycoprotein (G), a fusion protein (F), and / or a phosphoprotein (P).

Oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLN RNA and, in some cases, the amount of phosphoreceptor protein in a cell or animal are provided. Such oligomeric compounds, methods, and pharmaceutical compositions are useful for the treatment of cardiomyopathy, heart failure, or arrhythmia.

The present invention provides peptides that specifically bind to maternal autoantibodies that are generated in the mother or potential mother against one or more endogenous polypeptide antigens selected from lactate dehydrogenase A (LDH A), lactate dehydrogenase B (LDH B), stress-induced phosphoprotein 1 (STIP1), guanine deaminase (GDA), Y Box Binding Protein 1 (YBX1), collapsin response mediator protein 1 (CRMP1), and collapsin response mediator protein 2 (CRMP2). The peptides described herein are useful for determining a risk of an offspring for developing an autism spectrum disorder (ASD) by detecting the presence of maternal autoantibodies in a biological sample of the mother or potential mother. The peptides or mimotopes thereof can also be administered to the mother or potential mother to block the binding between maternal autoantibodies and their antigens, thereby neutralizing the maternal autoantibodies.

The present invention relates to a polypeptide composition, comprising a nucleic acid encoding a mutant pp65 polypeptide, the nucleic acid being mRNA, viral RNA, or replicon RNA. The composition is capable of expressing the mutant pp65 polypeptide in vivo, eliciting a specific humoral or cellular immune response against the pp65 polypeptide, and producing an effector cell having a tumor cell killing effect and a specific antibody.

The invention provides a pulp capping material comprising bioactive glass fibers, mesoporous tricalcium silicate, and zirconia dioxide. The initial setting time of this pulp capping material can be reduced to 7 minutes. The material exhibits no significant cytotoxicity and can significantly enhance cell viability. Additionally, it increases the expression of alkaline phosphatase and Dentin Sialophosphoprotein mineralization genes in dental pulp stem cells.

To provide novel nucleic acid sequences, vectors, modified cells, peptides, and pharmaceutical compositions which are useful in the treatment of human subjects, having a mutant nucleophosmin (ΔNPM1 or NPM1 mut) positive haematological malignancy.SOLUTION: The present invention provides an isolated nucleic acid sequence encoding (a) a polypeptide comprising a CDR3 of a TCR α chain polypeptide that specifically binds to a peptide selected from a specific group of sequences and / or (b) a polypeptide comprising a CDR3 of a TCR β chain polypeptide that specifically binds to a peptide selected from a specific group of sequences.SELECTED DRAWING: Figure 1

The invention provides application of phosvitin in preparation of a medicine for treating inflammatory bowel diseases. The inflammatory bowel disease comprises ulcerative colitis, and the ulcerative colitis is colitis induced by DSS (Di-Sulfate Sodium Sulfate). The phosvitin is natural protein extracted from eggs and has no adverse reaction on human bodies, and discomfort caused by long-term anti-inflammatory drug treatment is avoided. The phosvitin provided by the invention has the property of high net negative charge, so that the phosvitin has an anti-proteolysis effect, can resist a stomach high-acid environment, reaches intestinal tracts and exerts a curative effect.